A comparison of betahistine hydrochloride with placebo for vertebral-basilar insufficiency: a double-blind study.
To test the effectiveness of betahistine HC1 in reducing the frequency of transient ischemic attacks (TIAs) caused by vertebral-basilar artery insufficiency, we randomly assigned 26 patients with a typical history of the condition to a placebo-drug or a drug-placebo sequence, each sequence lasting two months. During the study, the frequency of TIAs did not differ significantly between the placebo and the drug groups. Subjective responses indicated some value for betahistine as a palliative agent.
D000328:Adult; D000368:Aged; D001488:Basilar Artery; D001621:Betahistine / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D002546:Ischemic Attack, Transient / Q000175:diagnosis / Q000517:prevention & control*; D008297:Male; D008875:Middle Aged; D010919:Placebos; D011725:Pyridines / Q000627:therapeutic use*; D014012:Tinnitus / Q000139:chemically induced; D014711:Vertebral Artery
D010919:Placebos; D011725:Pyridines; D001621:Betahistine